quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 15, 2026

Is It Time To Reassess UPS (UPS) After Recent Parcel Demand Headlines And Mixed Returns?

View original at finance.yahoo.com
“For United Parcel Service, the model used is a 2 Stage Free Cash Flow to Equity approach, based on Free Cash Flow in the last twelve months of about $4.3b.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • UPS currently scores 5 out of 6 on Simply Wall St's valuation checks

    60% confidence
  • Recent headlines have focused on UPS as a bellwether for parcel volumes, labor costs and broader freight demand

    60% confidence
  • UPS Free Cash Flow is estimated at $6.1 billion in 2026

    60% confidence
  • Analysts project UPS annual Free Cash Flow to reach $9.6 billion by 2035

    60% confidence
  • UPS Free Cash Flow is estimated at $7.6 billion in 2029

    60% confidence
  • UPS shares trade at about a 37.8% discount to intrinsic value based on DCF analysis

    60% confidence
  • United Parcel Service is undervalued by 37.8% according to DCF analysis

    60% confidence

Data points we hold from this source

United Parcel Service · free cash flow4.3 USD
United Parcel Service · intrinsic value per share166.04 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com